WO2012087255A3 - Formulations pharmaceutiques - Google Patents
Formulations pharmaceutiques Download PDFInfo
- Publication number
- WO2012087255A3 WO2012087255A3 PCT/TR2011/000274 TR2011000274W WO2012087255A3 WO 2012087255 A3 WO2012087255 A3 WO 2012087255A3 TR 2011000274 W TR2011000274 W TR 2011000274W WO 2012087255 A3 WO2012087255 A3 WO 2012087255A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- imatinib
- pharmaceutical formulations
- excipient
- weight
- range
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne des formulations d'imatinib renfermant un désintégrant pharmaceutiquement acceptable dans une proportion comprise entre 0,1 % et 5 % en poids et au moins un autre excipient.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2010/10618 | 2010-12-20 | ||
TR2010/10618A TR201010618A2 (tr) | 2010-12-20 | 2010-12-20 | İmatinib içeren bir oral dozaj formu ve bu oral dozaj formunun üretimi |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012087255A2 WO2012087255A2 (fr) | 2012-06-28 |
WO2012087255A3 true WO2012087255A3 (fr) | 2012-08-16 |
Family
ID=45529174
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/TR2011/000274 WO2012087255A2 (fr) | 2010-12-20 | 2011-12-19 | Formulations pharmaceutiques |
PCT/TR2011/000276 WO2012087257A2 (fr) | 2010-12-20 | 2011-12-19 | Forme galénique orale contenant de l'imatinib et production de ladite forme galénique orale |
PCT/TR2011/000275 WO2012087256A2 (fr) | 2010-12-20 | 2011-12-19 | Formulations de capsules pharmaceutiques |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/TR2011/000276 WO2012087257A2 (fr) | 2010-12-20 | 2011-12-19 | Forme galénique orale contenant de l'imatinib et production de ladite forme galénique orale |
PCT/TR2011/000275 WO2012087256A2 (fr) | 2010-12-20 | 2011-12-19 | Formulations de capsules pharmaceutiques |
Country Status (2)
Country | Link |
---|---|
TR (1) | TR201010618A2 (fr) |
WO (3) | WO2012087255A2 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL394169A1 (pl) * | 2011-03-09 | 2012-09-10 | Adamed Spółka Z Ograniczoną Odpowiedzialnością | Kompozycja farmaceutyczna metanosulfonianu imatinibu do napełniania jednostkowych postaci dawkowania oraz sposób jej wytwarzania |
KR20140065862A (ko) * | 2012-11-22 | 2014-05-30 | 에스케이케미칼주식회사 | 발포성 속붕해성 이매티닙 제제 |
GB201304699D0 (en) * | 2013-03-15 | 2013-05-01 | Remedica Ltd | Pharmaceutical compositions |
ES2683361T3 (es) * | 2013-05-14 | 2018-09-26 | Hetero Research Foundation | Composiciones de Imatinib |
EP3019159A4 (fr) * | 2013-07-09 | 2017-01-18 | Shilpa Medicare Limited | Compositions pharmaceutiques orales comprenant du mésylate d'imatinib |
TWI608849B (zh) * | 2014-06-16 | 2017-12-21 | 國邑藥品科技股份有限公司 | 可調控釋放度之高載藥量之醫藥組合物及其製備方法 |
EP3257499A1 (fr) | 2016-06-17 | 2017-12-20 | Vipharm S.A. | Procédé pour la préparation de capsules de méthanesulfonate d'imatinib |
WO2019229648A1 (fr) * | 2018-05-28 | 2019-12-05 | Shivalik Rasayan Limited | Compositions orales de mésylate d'imatinib |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060275372A1 (en) * | 2005-06-03 | 2006-12-07 | Elan Pharma International Limited | Nanoparticulate imatinib mesylate formulations |
US20070036850A1 (en) * | 2005-08-15 | 2007-02-15 | Siegfried Generics International Ag | Film-coated tablet or granules containing as active ingredient a pyridylpyrimidine compound or a pharmaceutically acceptable salt of this compound |
US20090087489A1 (en) * | 2007-09-25 | 2009-04-02 | Bella Gerber | Imatinib compositions |
US20090221519A1 (en) * | 1999-12-27 | 2009-09-03 | Novartis Ag | Combinations of receptor tyrosine kinase inhibitor with an a1-acidic glycoprotein binding compound |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW225528B (fr) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
GB2398565A (en) | 2003-02-18 | 2004-08-25 | Cipla Ltd | Imatinib preparation and salts |
MY148074A (en) * | 2005-05-10 | 2013-02-28 | Novartis Ag | Pharmaceutical compositions comprising imatinib and a release retardant |
US20060223817A1 (en) | 2006-05-15 | 2006-10-05 | Chemagis Ltd. | Crystalline imatinib base and production process therefor |
CA2662265A1 (fr) * | 2006-09-01 | 2008-03-06 | Teva Pharmaceutical Industries Ltd. | Compositions d'imatinib |
-
2010
- 2010-12-20 TR TR2010/10618A patent/TR201010618A2/xx unknown
-
2011
- 2011-12-19 WO PCT/TR2011/000274 patent/WO2012087255A2/fr active Application Filing
- 2011-12-19 WO PCT/TR2011/000276 patent/WO2012087257A2/fr active Application Filing
- 2011-12-19 WO PCT/TR2011/000275 patent/WO2012087256A2/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090221519A1 (en) * | 1999-12-27 | 2009-09-03 | Novartis Ag | Combinations of receptor tyrosine kinase inhibitor with an a1-acidic glycoprotein binding compound |
US20060275372A1 (en) * | 2005-06-03 | 2006-12-07 | Elan Pharma International Limited | Nanoparticulate imatinib mesylate formulations |
US20070036850A1 (en) * | 2005-08-15 | 2007-02-15 | Siegfried Generics International Ag | Film-coated tablet or granules containing as active ingredient a pyridylpyrimidine compound or a pharmaceutically acceptable salt of this compound |
US20090087489A1 (en) * | 2007-09-25 | 2009-04-02 | Bella Gerber | Imatinib compositions |
Non-Patent Citations (1)
Title |
---|
"Stable Tablet Formulation containing more than 80% of Imatinib mesylate", IP.COM JOURNAL, IP.COM INC., WEST HENRIETTA, NY, US, 19 February 2008 (2008-02-19), XP013123894, ISSN: 1533-0001 * |
Also Published As
Publication number | Publication date |
---|---|
WO2012087257A3 (fr) | 2012-09-27 |
WO2012087255A2 (fr) | 2012-06-28 |
WO2012087257A2 (fr) | 2012-06-28 |
WO2012087256A3 (fr) | 2012-09-27 |
TR201010618A2 (tr) | 2012-07-23 |
WO2012087256A2 (fr) | 2012-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012087255A3 (fr) | Formulations pharmaceutiques | |
EP3626253A3 (fr) | Formulations stables de linaclotide | |
HK1152478A1 (en) | Solid pharmaceutical formulations comprising bibw 2992 | |
WO2011076749A3 (fr) | Forme solide de dosage pharmaceutique | |
WO2014045162A8 (fr) | Composés d'hexahydropyrano[3,4-d][1,3]thiazine-2-amine alkyl-substitués | |
WO2010000877A3 (fr) | Formulation à base de bisabolol et de [6]-paradol produisant un effet apaisant sur les irritations | |
WO2010146179A3 (fr) | Composition pharmaceutique solide comprenant du rivaroxaban | |
WO2012051559A3 (fr) | Compositions et méthodes de traitement de l'hypertension artérielle pulmonaire | |
NI201100227A (es) | Composiciones de dosis fija farmacéuticas sólidas que comprenden irbesartán y amlodipina, su preparación y su aplicación terapéutica. | |
WO2012101653A3 (fr) | Compositions pharmaceutiques de mémantine à libération modifiée | |
WO2013106068A3 (fr) | Compositions thérapeutiques de préparations déterminées à base de plantes, et leurs utilisations | |
WO2008129501A3 (fr) | Compositions pharmaceutiques de duloxetine | |
WO2013057741A3 (fr) | Compositions pharmaceutiques d'acide ursodésoxycholique | |
WO2010049449A3 (fr) | Nouveaux sels de sunitinib | |
EP2241310A3 (fr) | Formulations à libération modifiée d'émoxypine | |
WO2012085284A3 (fr) | Formulations pharmaceutiques à charge médicamenteuse élevée comprenant de la dronédarone et des sels pharmaceutiquement acceptables de celles-ci | |
WO2011064558A3 (fr) | Composition pharmaceutique | |
WO2011142731A3 (fr) | Formulations comprenant une céphalosporine et un acide clavulanique de troisième génération | |
JO3587B1 (ar) | أشكال جرعات بينداموستين عن طريق الفم | |
EP2196463A4 (fr) | Procédé de préparation d'acide 5,6-diméthylxanthone-acétique, dérivés ainsi obtenus et formulations pharmaceutiques de ceux-ci | |
WO2010079433A3 (fr) | Composition pharmaceutique qui comprend un inhibiteur de la dipeptidyl peptidase-iv | |
GB201223190D0 (en) | A novel herbal formulation advocated for the prevention and management of coronary heart disease | |
WO2011156045A3 (fr) | Formulation d'ezatiostat en comprimés | |
WO2010149794A3 (fr) | Nouvelle composition pharmaceutique comprenant du poly(allylamine-co-n,n'-diallyl-1,3-diamino-2-hydroxypropane) | |
WO2011139253A3 (fr) | Compositions pharmaceutiques comprenant du ceftibutène |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11811588 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11811588 Country of ref document: EP Kind code of ref document: A2 |